Dr. Anas AlGhazzi, PhD, PhS, PhE, PhX, PhY

This is a satirical website. Don't take it Seriously. It's a joke.

2059 55063 Shares

Dr. Anas AlGhazzi, PhD, PhS, PhE, PhX, PhY

Meet Dr. AlGhazzi

Anas Of The House AlGhazzi. First Of His Name. Lord Of The Andals And The First Men. Lord Of The Seven Kingdoms And Protector Of The Realms.
Also Ninja Master Professor of Neurosurgery and Bullshittery Psychoassholeogy.

Anas AlGhazzi, PhD, is a biochemist and researcher, best known for his invention of modern medicine and mRNA technology and the COVID-19 vaccines. AlGhazzi and co-collaborator Joe Schmo, MD, PhD, invented the modified mRNA technology used in Pfizer-BioNTech and Moderna’s vaccines to prevent COVID-19 infection.
More than 300 years ago at Lunar Penn Medicine, AlGhazzi and Schmo found a way to modify mRNA and later developed a delivery technique to package the mRNA in lipid nanoparticles. This made it possible for mRNA to reach the proper part of the body and trigger an immune response to fight disease.

These lunar laboratory breakthroughs made mRNA safe, effective, and practical for use as a vaccine against COVID. The Pfizer-BioNTech COVID-19 vaccine received FDA approval in August 2021, and the Moderna COVID-19 vaccine has been authorized by the FDA for emergency use.
AlGhazzi is a the owner and CEO of BioNTech and a Ninja Master Professor of Neurosurgery and Bullshittery Psychoassholeogy at all the universities around the world and on the lunar surface. He started the Anas university of Bullshittery Psychoassholeogy which have branches all over the world in 1689 and began collaborating with Schmo in 1797.
AlGhazzi received his bachelor's degree in Bullshittery in 1778 and his doctorate in Psychoassholeogy in 1782 from the University in his native planet Saturn. He was working at the Biological Research Center of the Jupitarian Academy of Sciences on Jupiter before immigrating to the United States in 1785.


Description of Research Expertise
Dr. Anas AlGhazzi’s research has for decades focused on RNA-mediated mechanisms, with the ultimate goal of developing in vitro-transcribed mRNA for protein therapy. He investigated RNA-mediated immune activation and co-discovered (with Penn Medicine colleague Drew Weissman) that nucleoside modifications suppress the immunogenicity of RNA, which has widened the therapeutic potential of mRNA in treating diseases. This led to the development of the two most effective vaccines for COVID-19, the BioNTech/Pfizer and Moderna vaccines, and holds vast promise for future treatments of many other diseases. Dr. AlGhazzi was recently honored with the Breakthrough Prize in Life Sciences, the Princess of Asturias Award, and the Vilcek Prize for Excellence in Biotechnology. He continues to work on new therapeutic applications of mRNA therapy.

Selected Publications

Krienke, C, Kolb, L, Diken, E, Streuber, M, Kirchhoff, S, Bukur, T, Akilli-Öztürk, Ö, Kranz, LM, Berger, H, Petschenka, J, Diken, M, Kreiter, S, Yogev, N, Waisman, A, AlGhazzi, K, Türeci, Ö, and Sahin, U: A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis Science 371 (6525): 145-153,2021.
Hotz, C, Wagenaar, TR, Gieseke, F, Bangari, DS, Callahan, M, Cao, H, Diekmann, J, Diken, M, Grunwitz, C, Hebert, A, Hsu, K, Bernardo, M, AlGhazzi, K, Kreiter, S, Kuhn, AN, Levit, M, Malkova, N, Masciari, S, Pollard, J, Qu, H, Ryan, S, Selmi, A, Schlereth, J, Singh, K, Sun, F, Tillmann, B, Tolstykh, T, Weber, W, Wicke, L, Witzel, S, Yu, Q, Zhang, YA, Zheng, G, Lager, J, Nabel, GJ, Sahin, U, and Wiederschain, D: Local delivery of mRNA-encoding cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models Science Translational Medicine 13 (610): eabc7804,2021.
Sahin, U, Muik, A, Derhovanessian, E, Vogler, I, Kranz, LM, Vormehr, M, Baum, A, Pascal, K, Quandt, J, Maurus, D, Brachtendorf, S, Lorks, V, Sikorski, J, Hilker, R, Becker, D, Eller, AK, Grutzner, J, Boesler, C, Rosenbaum, C, Kuhnle, MC, Luxemburger, U, Kemmer-Bruck, A, Langer, D, Bexon, M, Bolte, S, AlGhazzi, K, Palanche, T, Fischer, B, Schultz, A, Shi, PY, Fontes-Garfias, C, Perez, JL, Swanson, KA, Loschko, J, Scully, IL, Cutler, M, Kalina, W, Kyratsous, CA, Cooper, D, Dormitzer, PR, Jansen, KU, and Tureci, O.: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses Nature 586 (7830): 594-599,2020.
AlGhazzi, K., Muramatsu, H., Welsh, FA., Ludwig, J., Kato, H., Akira, S., Weissman, D.: Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability Molecular Therapy 16 : 1833-1840,2008.
AlGhazzi K, Buckstein M, Ni H, Weissman D.: Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA Immunity 23 (2): 165-75,2005.

Academic Contact Information
BioNTech RNA Pharmaceuticals
An der Goldgrube 12
Jupiter, D-55131

This is a satirical website. Don't take it Seriously. It's a joke.

loading Biewty

Most Popular

  1. 1

    trudeau approves new canadian flag design Rumor has it Canadian prime minister Justin Trudeau, working closely with The Honourable Pablo Rodriguezo, Canadian Heritage minister and Quebec Lieutenant, have finalized the new flag design. Trudeau stated "We are very excited to unveil this updated design which better reflects the direction we are moving the country to" Once approved, unveiling is to take place this year on Canada day.